The group has devoted the last five years to assembling, implementing and validating a novel technological platform that allows us to analyze the N-glycome from minute amounts of biological samples: sera, plasma or tissues, unique at the UAM campus and second in Spain, and fourth in Europe behind Croatia and Ireland. The group has curated one of the largest collections of clinically well-characterized biological samples of American tripanosomiasis biological samples (around 5000), leishmaniasis visceral and Neurocisticercosis from all stages of the diseases, before and after chemotherapeutic treatment.

The glycomic evaluation of individuals (not populations) allows to establish associations to disease progression, therapeutic efficacy or failure and reinfections. The system has been used to analyze samples from three defined infectious diseases from which we have clinically defined cohorts (Chagas disease, Leishmaniasis and Neurocysticercosis). From our previous studies on total sera N-glycome we have moved to study the effector profile of human Immunoglobulin G derived from its glycosylation profile. By using this novel approach, we have been allowed to identify some molecular markers for efficacy during the treatment with Benznidazole for acute Chagas disease patients and able to discriminate the latent form active form of neurocysticercosis, previously only possible by using classical image systems like NMR or PET-TAC.